Physician profile
Ernesto Grenier
NPI 1366614927
$8,304.18
in general payments reported to CMS, 2019-2025
16 companies · $910 in 2025
The $910 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $601 · 2021: $1,432 · 2022: $1,707 · 2023: $1,514 · 2024: $881 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,200 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,200.33 |
| Education | $104.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,328.39 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $1,176.02 | 2019-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $970.21 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $857.07 | 2019-2023 | Ingrezza |
| Alkermes, INC. | $756.13 | 2019-2025 | Aristada, Vivitrol, Lybalvi |
| Abbvie INC. | $712.62 | 2022-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $347.03 | 2022-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $296.49 | 2023-2024 | Caplyta |
| Pear Therapeutics (US), INC. | $288.37 | 2021 | |
| Idorsia Pharmaceuticals US INC | $124.59 | 2023 | Quviviq |
| Johnson & Johnson Health Care Systems INC. | $120.24 | 2019 | |
| Indivior INC. | $84.63 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $65.45 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $65.37 | 2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $56.54 | 2019-2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $55.03 | 2023-2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernesto Grenier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.